Institute of Social and Preventive Medicine (ISPM), University of Bern
Bern, Canton of Bern, 3012, Switzerland
NCT Number: NCT01875042
The proposed study is a multi-center, randomized, double blind (patient and assessor), sham controlled clinical trial using a parallel 2 group design recruiting 220 patients of at least 18 years of age. The investigators will include patients presenting with clinically and radiologically diagnosed knee OA according to the criteria of the American College of Rheumatology, who experienced knee pain lasting for at least six months, and were diagnosed with radiographic severity of ≥ 2 on the Kellgren-Lawrence grading system or had one or more of the following signs and symptoms in the knee; restricted range of motion, pain in motion, crepitations, morning stiffness. Patients will be randomly allocated to receive TENS or sham TENS for 3 weeks.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Bern, Canton of Bern, 3012, Switzerland
Background
Osteoarthritis (OA) is the most common arthritic condition, which is one of the leading causes of disability in adults. Currently, no treatment can stop or reverse the progressive joint degeneration caused by OA. Most clinical interventions aim to improve pain and physical function. Transcutaneous electrical nerve stimulation (TENS) is widely used in the management of knee OA to relieve osteoarthritic pain and facilitate the performance of therapeutic activities in order to maintain or improve physical function. Although its use is widespread, the available evidence is of questionable quality. An adequately sized and well conducted randomized controlled trial (RCT) investigating the effectiveness and safety of TENS as treatment modality for knee OA is warranted to assist clinicians and policy makers to make decisions that are based on high-quality evidence, ultimately optimizing delivery of health-care in knee OA.
Objective
To determine TENS safety and effectiveness on pain and physical function compared to sham TENS in patients with knee OA.
Methods
Multi-center, randomized, double blind (patient and assessor), sham controlled clinical trial using a parallel 2 group design. Patients will be randomly allocated to receive TENS or sham TENS for 3 weeks. Informed consent of eligible patients will be obtained prior to randomization. Patients will be assigned on a 1:1 basis to the TENS or sham TENS group. Randomization will be centralized using randomization software and an electronic randomization form, generated by the trial coordinating centre (CTU Bern). Patients will be randomized once demographic data and selection criteria are completed by the recruiting physician in an electronic form. Randomization will be stratified according to treatment centre, TENS naivety and clinical severity.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Transcutaneous electrical nerve stimulation
Sham Transcutaneous electrical nerve stimulation
Time frame: End of treatment (at 3 weeks)
Time frame: Baseline, end of treatment (at 3 weeks), 3-month follow-up
Time frame: Baseline, end of treatment (at 3 weeks), 3-month follow-up
Time frame: Baseline, end of treatment (at 3 weeks), 3-month follow-up
Time frame: Baseline, end of treatment (at 3 weeks), 3-month follow-up
Time frame: Baseline, end of treatment (at 3 weeks), 3-month follow-up
Time frame: Baseline, end of treatment (at 3 weeks), 3-month follow-up
Time frame: End of treatment (at 3 weeks), 3-month follow-up
Time frame: End of treatment (at 3 weeks), 3-month follow-up
Time frame: End of treatment (at 3 weeks), 3-month follow-up
Time frame: End of treatment (at 3 weeks), 3-month follow-up
Time frame: End of treatment (at 3 weeks), 3-month follow-up
Time frame: Baseline, third treatment session, 3-month follow-up
Insel Gruppe AG, University Hospital Bern
Other
Does Transcutaneous Electrical Nerve Stimulation (TENS) Affect Pain and Function in Patients With Osteoarthritis of the Knee? ETRELKA, a Randomised Controlled Trial
Acronym: ETRELKA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07364578
Arthritis, Joint Diseases
Banī Suwayf, Egypt
View Trial DetailsNCT03895489
Arthritis, Joint Diseases
Edmonton, Alberta, Canada
View Trial DetailsNCT06693648
Arthritis, Joint Diseases
Thousand Oaks, California, United States
View Trial DetailsNCT06522906
Arthritis, Behavior
Tucson, Arizona, United States
View Trial Details